Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Top small molecule API pharma CMOs gain high containment facilities but decrease non-specialized sites, says GlobalData

Top pharma Contract Manufacturing Organizations (CMOs) are investing in specialist facilities for manufacturing small molecule active pharmaceutical ingredients (API) requiring containment, according to the GlobalData report, ‘Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition’. High containment facilities protect operators against exposure to dangerous products and prevent cross-contamination of standard medicines with […]
Read more

Promising pipeline for endometriosis will transform treatment algorithm, says GlobalData

Oral contraceptives and non-steroidal anti-inflammatory drugs (NSAIDs) remain first-line therapies in the endometriosis market across the seven major markets (7MM*) due to their affordability, side effect profiles and ease of use. However, the treatment algorithm for endometriosis will see significant changes given the promising pipeline, which includes GnRH antagonists, Relugolix and Linzagolix, and a vaginal […]
Read more

Abbott Laboratories growth in 2021 driven by rapid diagnostics, in global market worth $54.4 billion, says GlobalData

Following the release of Q4 2021 financials from Abbott Laboratories; Chris Onderisin, Medical Devices Analyst at GlobalData, a leading data and analytics company, offers his view: “A steady rise in sales of COVID-19 rapid diagnostics has allowed Abbott Laboratories to increasingly gain ground in the global in vitro diagnostics market, which GlobalData values at $54.4 […]
Read more

US sickle cell disease market to skyrocket to $4.8bn by 2030, driven by gene therapies and new first-in-class products, says GlobalData

A number of exciting new sickle cell disease (SCD) drugs are set to hit the US market, says GlobalData, including gene therapies that could offer patients a cure. The leading data and analytics company notes that one of the gene therapies that is currently closest to entering the market— bluebird bio‘s bb1111—is projected to represent […]
Read more

Roche’s tominersen could help Huntington’s disease market reach over $1 billion in sales by 2030, says GlobalData

Ionis Pharmaceuticals’ partner Roche recently announced that it will initiate a new Phase II trial to reassess its pipeline antisense therapy, tominersen, in the treatment of Huntington’s disease (HD). Tominersen offers Roche the opportunity to bring one of the first disease-modifying treatments to this market, in a move that could help nudge the HD market […]
Read more

Psoriasis small molecule market expected to grow significantly over the next 10 years, says GlobalData

On January 13, UNION Therapeutics registered a Phase IIb, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of the phosphodiesterase-4 (PDE4) inhibitor, orismilast, in adults with moderate-to-severe plaque psoriasis (PsO). Although historically dormant compared to the injectable biologic development space, the PsO small molecule market is expected to grow significantly over […]
Read more

Rinvoq and Cibinqo Janus kinase (JAK) inhibitors approved by FDA with boxed warnings and restrictive labelling, says GlobalData

AbbVie’s Rinvoq (upadacitinib) and Pfizer’s Cibinqo (abrocitinib) have been approved by the FDA for the treatment of refractory atopic dermatitis (AD), despite ongoing safety concerns and multiple delays. Both AbbVie and Pfizer’s products assets are the first small molecules, specifically Janus kinase (JAK)-1 inhibitors, to be approved in the US, as treatment options for patients […]
Read more

AVROBIO Fabry disease gene therapy program cancelled inhibiting the company’s progress in rare diseases, says GlobalData

AVROBIO has cancelled its Fabry disease (FD) gene therapy AVR-RD-01, which was due to launch in H2 2022 following disappointing results from a recent Phase II clinical trial. In earlier clinical trials the company had reported promising results for AVR-RD-01 with these recent poor results occurring unexpectedly. This will prove to be significantly disappointing to […]
Read more

Novavax continues to strengthen Asia presence with South Korea approval, says GlobalData

American biotech company Novavax, together with Korea-based SK Group’s vaccine business subsidiary SK bioscience, has secured the South Korea’s Ministry of Food and Drug Safety (MFDS) approval for its recombinant, adjuvanted COVID-19 vaccine Nuvaxovid. The move strengthens Novavax’s presence in Asia through local partners, says GlobalData, a leading data and analytics company. According to GlobalData’s […]
Read more

T-cell lymphoma diagnosed incident cases set to reach 35,000 in 2030, driven by an aging population with more risk factors and comorbid conditions, says GlobalData

Driven by an aging population and more people with comorbid conditions, the amount of patients diagnosed with T-cell lymphoma (TCL) is expected to increase at an annual growth rate (AGR) of 3.00% from around 27,000 cases in 2020 to 35,000 cases in 2030 in the eight major markets (8MM*), according to GlobalData. The leading data […]
Read more

Unmet needs in Duchenne muscular dystrophy will be partially met by the pipeline, says GlobalData

Upcoming, highly-anticipated gene therapies for progressive muscle-degenerating disease Duchenne muscular dystrophy (DMD) will cost a whopping $2 million per patient per year—double the cost of the current standard-of-care, exon-skipping therapies—says GlobalData. The leading data and analytics company’s research highlighted the costs of various DMD treatment types as part of an assessment of the upcoming pipeline, […]
Read more

Cejemly will drive CStone’s overall growth in China, says GlobalData

CStone Pharmaceuticals has recently received the National Medical Products Administration (NMPA) of China approval for Cejemly (sugemalimab). Against this backdrop, Cejemly is expected to drive the CStone’s overall growth, says GlobalData, a leading data and analytics company. Cejemly is an OmniAb-derived anti-PD-L1 monoclonal antibody for the first-line treatment of metastatic (stage IV) non-small cell lung […]
Read more
1 … 52 53 54 55 56 … 110